L. Roy Papp & Associates LLP lifted its holdings in shares of Johnson & Johnson (NYSE:JNJ – Free Report) by 0.4% in the 1st quarter, according to its most recent Form 13F filing with the SEC. The firm owned 113,337 shares of the company’s stock after buying an additional 464 shares during the period. Johnson & Johnson makes up approximately 2.4% of L. Roy Papp & Associates LLP’s holdings, making the stock its 11th largest position. L. Roy Papp & Associates LLP’s holdings in Johnson & Johnson were worth $17,567,000 as of its most recent filing with the SEC.
Other hedge funds have also made changes to their positions in the company. GW&K Investment Management LLC acquired a new stake in Johnson & Johnson in the fourth quarter valued at about $35,000. Dark Forest Capital Management LP lifted its position in Johnson & Johnson by 1,044.4% in the fourth quarter. Dark Forest Capital Management LP now owns 206 shares of the company’s stock valued at $36,000 after purchasing an additional 188 shares during the period. Ruedi Wealth Management Inc. acquired a new stake in Johnson & Johnson in the fourth quarter valued at about $42,000. Kepos Capital LP acquired a new stake in Johnson & Johnson in the fourth quarter valued at about $45,000. Finally, VitalStone Financial LLC purchased a new position in Johnson & Johnson in the fourth quarter valued at about $52,000. Institutional investors and hedge funds own 67.57% of the company’s stock.
Johnson & Johnson Stock Up 1.0 %
JNJ stock opened at $173.85 on Friday. The stock has a market capitalization of $451.83 billion, a P/E ratio of 35.19, a PEG ratio of 2.90 and a beta of 0.54. The company has a debt-to-equity ratio of 0.44, a quick ratio of 0.88 and a current ratio of 1.12. Johnson & Johnson has a one year low of $150.11 and a one year high of $181.04. The company has a 50 day moving average price of $164.56 and a two-hundred day moving average price of $161.21.
Johnson & Johnson Announces Dividend
The business also recently declared a quarterly dividend, which will be paid on Thursday, September 7th. Shareholders of record on Monday, August 28th will be issued a $1.19 dividend. The ex-dividend date of this dividend is Friday, August 25th. This represents a $4.76 dividend on an annualized basis and a dividend yield of 2.74%. Johnson & Johnson’s dividend payout ratio (DPR) is presently 96.36%.
Analyst Upgrades and Downgrades
A number of brokerages have issued reports on JNJ. Atlantic Securities increased their target price on shares of Johnson & Johnson from $167.00 to $170.00 and gave the company a “neutral” rating in a report on Friday, August 4th. Citigroup began coverage on shares of Johnson & Johnson in a report on Tuesday, May 30th. They issued a “buy” rating and a $185.00 target price for the company. Stifel Nicolaus increased their target price on shares of Johnson & Johnson from $165.00 to $175.00 in a report on Friday, July 21st. Morgan Stanley reaffirmed an “equal weight” rating and issued a $187.00 target price on shares of Johnson & Johnson in a report on Friday, July 21st. Finally, Barclays increased their target price on shares of Johnson & Johnson from $171.00 to $175.00 and gave the company an “equal weight” rating in a report on Monday, July 24th. Eight analysts have rated the stock with a hold rating, four have given a buy rating and one has given a strong buy rating to the company. Based on data from MarketBeat, the stock has an average rating of “Hold” and a consensus target price of $171.80.
Read Our Latest Research Report on Johnson & Johnson
Insider Buying and Selling at Johnson & Johnson
In other Johnson & Johnson news, EVP Kathryn E. Wengel sold 12,465 shares of Johnson & Johnson stock in a transaction on Monday, June 12th. The shares were sold at an average price of $160.00, for a total value of $1,994,400.00. Following the transaction, the executive vice president now owns 65,934 shares in the company, valued at approximately $10,549,440. The sale was disclosed in a document filed with the SEC, which can be accessed through the SEC website. In other Johnson & Johnson news, VP Peter Fasolo sold 20,000 shares of Johnson & Johnson stock in a transaction on Tuesday, July 25th. The shares were sold at an average price of $170.32, for a total value of $3,406,400.00. Following the transaction, the vice president now owns 102,696 shares in the company, valued at approximately $17,491,182.72. The sale was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, EVP Kathryn E. Wengel sold 12,465 shares of Johnson & Johnson stock in a transaction on Monday, June 12th. The shares were sold at an average price of $160.00, for a total transaction of $1,994,400.00. Following the completion of the transaction, the executive vice president now owns 65,934 shares in the company, valued at approximately $10,549,440. The disclosure for this sale can be found here. Insiders have sold a total of 47,163 shares of company stock worth $7,928,856 in the last quarter. 0.20% of the stock is owned by insiders.
Johnson & Johnson Company Profile
Johnson & Johnson, together with its subsidiaries, researches, develops, manufactures, and sells various products in the healthcare field worldwide. The company's Consumer Health segment provides skin health/beauty products under the AVEENO, CLEAN & CLEAR, DR. CI:LABO, NEUTROGENA, and OGX brands; baby care products under the JOHNSON'S and AVEENO Baby brands; oral care products under the LISTERINE brand; TYLENOL acetaminophen products; SUDAFED cold, flu, and allergy products; BENADRYL and ZYRTEC allergy products; MOTRIN IB ibuprofen products; NICORETTE smoking cessation products; and PEPCID acid reflux products.
Featured Articles
- Five stocks we like better than Johnson & Johnson
- Consumer Staples Stocks, Explained
- Investing in Coffee: 3 Great Strategies to Consider
- What Are Dividend Challengers?
- 5 Best Stocks to Buy in a Bear Market
- How to Invest in Virtual Reality
- 3 Pharmaceutical Stocks to Buy and Hold for the Long Haul
Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.
